
    
      This is a single-arm, multicenter, open-label Phase 2 study to evaluate efficacy, safety,
      tolerability of zanubrutinib in participants with relapsed/refractory non-GCB type Diffuse
      Large B Cell Lymphoma.

      The study will enroll approximately 40 participants treated with zanubrutinib 160mg BID. All
      participants in the study will be treated until disease progression, unacceptable toxicity,
      death, withdrawal of consent, or the study is terminated by the sponsor for final analysis.
      At the time of final analysis, participants who remain on treatment will be considered for
      participation in the extension study when eligible. A treatment cycle consists of 28 days.
    
  